GGV Capital has led an extended Series A round of funding for Ypzdw.com, a Chinese online B2B drug retail platform. Existing investor Matrix Partners China also participated.
Sequoia Capital has committed $20 million in Series B funding to Indian genomic diagnostic and research service provider MedGenome.
Healthcare specialist Vivo Capital has led a Series B round of funding for Gengmei, a Chinese cosmetic surgery social networking app, with participation from Sequoia Capital.
KKR has completed its second social enterprise assistance project alongside Impact Investment Exchange Asia (IIX) and its non-profit sister organization Shujog, providing support to Glovax Biotech, which sells affordable vaccines to low to middle income...
FountainVest Partners has led a RMB200 million ($32 million) round of funding for Xingren.com, a Chinese mobile app for doctors to communicate with patients. Existing investors Sequoia Capital and Lightspeed China Partners also participated.
Tiger Global has led a $10.2 million Series B round investment in Indian doctor search app Lybrate.
US early stage investor Founders Fund and Japanese conglomerate Mitsui & Co have together invested JPY620 million ($5.1 million) in Genesis Healthcare, a Tokyo-based start-up that develops genetic testing kits, in exchange for a 6% stake.
Cathay Capital Private Equity has invested an undisclosed sum in Cenexi Group, a French pharmaceutical contract manufacturer.
China-focused food and agriculture specialist Hosen Capital is looking to raise $400 million for its second US dollar-denominated fund.
On the back of reforms and a rising consumer class, China's healthcare sector is expected to see huge growth. Sector specialists have emerged to capitalize on the opportunity. How can they differentiate themselves?
Australian cancer and cardiovascular treatment provider GenesisCare, which is owned by KKR, has bought cancer center manager Cancer Partners UK from its private equity backer, Apposite Capital.
China VC firm Qiming Venture Partners has promoted healthcare specialist William Hu to managing partner with immediate effect.
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Roger Hu, a director at Matrix Partners China, has teamed up with Yi Zheng, formerly vice president at Chinese dating app Momo, to launch a renminbi-denominated early-stage fund.
Crescent Capital Partners has agreed to acquire the Australian pathology operations of Healthscope for A$105 million ($80.8 million).
Singapore's Temasek Holdings is a member of a CVC Capital Partners-led consortium that has agreed to buy a controlling stake in US-based generic drug manufacturer Alvogen. The deal is said to value the company at $2 billion.
Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China backed by PE investors, has filed for an IPO in Hong Kong.
Indian dental clinic chain MyDentist has raised a INR500 million ($8 million) funding round led by Swiss impact investor LGT Venture Philanthropy, with participation by existing backers Seedfund and Asian Healthcare Fund (AHF).
For the past decade, Japan’s universities have been working with venture capital to commercialize their research. Recent developments in the public and private sectors suggest this relationship is evolving
La Renon, an Indian developer and manufacturer of pharmaceutical drugs and services, has raised INR1 billion ($16 million) in Series A funding from Sequoia Capital.
Neil Shen, managing partner at Sequoia Capital China, is supporting take-private bids for budget hotel operator Home Inns and online real estate agency E-House as a growing number of US-listed Chinese companies turn their attention to domestic listings.
Warburg Pincus has raised $241.5 million by reducing its stake in US-listed biopharmaceutical developer China Biologic Products.
Panasonic Healthcare, the Japanese medical equipment manufacturer in which KKR acquired a majority stake last year, has agreed to buy Bayer’s diabetes care business for EUR1.02 billion ($1.15 billion).